Orchid Pharma Limited has informed the Exchange regarding 'Update on purchase of Assets of Allecra Therapeutics SAS'.

Listed-company acquisitionStrategic Transactions View source PDF Explain this filing

ORCHPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.6%Reaction day

₹784.00

prior close

₹785.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.1%-2.5% vs market

Pharmaceuticals peers, median of 149sector-1.7%-1.9% vs sector

On the reaction day the stock moved 2.5 pts less than Nifty Microcap 250 and 1.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

+0.3

15m

-0.3

30m

-1.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.6-1.1-2.5-1.7-1.9

Next day

-3.2-1.4-1.8-1.4-1.8

-3.6-2.2-1.3-2.0-1.6

-0.9-2.0+1.1-2.0+1.2

-2.7-2.0-0.7-1.7-0.9

-2.6-1.4-1.2-1.8-0.8

-3.9-0.7-3.2-1.9-1.9

15d

-6.3-2.5-3.7-3.6-2.7

-9.8+0.3-10.0-2.5-7.3

-5.4-0.7-4.7-3.3-2.1

+4.0-0.6+4.6-5.7+9.6

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 149Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Orchid Pharma Limited has received approval from the French Court to acquire the assets of Allecra Therapeutics SAS, effective August 01, 2025. This is an update to the company's earlier intimation dated July 30, 2025, regarding the asset purchase. Allecra Therapeutics is a France-based pharmaceutical company, and the involvement of a French court suggests the acquisition is being executed through a judicial or insolvency process. With the court order now in favor of Orchid Pharma, the company can formally proceed to take over Allecra's assets. The deal expands Orchid Pharma's asset base in the specialty pharmaceuticals space, though financial terms and the exact nature of assets being acquired were not disclosed in this filing.

Likely market impact

Positive for shareholders as the acquisition strengthens Orchid Pharma's product portfolio and pipeline, potentially adding new therapeutic assets and IP from Allecra Therapeutics. The court approval removes a key legal hurdle and signals that the deal is now moving forward for completion.